URSODIOL (ursodiol) by Gen Pharmaceuticals is clinical pharmacology about 90% of a therapeutic dose of ursodiol is absorbed in the small bowel after oral administration. Approved for gallstone formation in obese patients experiencing rapid weight loss. First approved in 2020.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY About 90% of a therapeutic dose of ursodiol is absorbed in the small bowel after oral administration. After absorption, ursodiol enters the portal vein and undergoes efficient extraction from portal blood by the liver (i.e., there is a large "first-pass" effect) where it is…
Worked on URSODIOL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bile Acid
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Ursodiol in Huntington's Disease
Ursodiol Tablets 500 mg Under Fasting Conditions
Ursodiol 500 mg Tablets Under Fed Conditions